Do analysts rate ACB or CARA?

Aurora Cannabis presently has a consensus price target of C$6.67, suggesting a potential upside of 9.11%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, equities analysts plainly believe Aurora Cannabis is more favorable than Cara Operations. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, ACB or CARA?

Cara Operations has lower revenue, but higher earnings than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis C$314.07M 1.21 -C$44.16M -C$1.94 N/A Cara Operations N/A N/A N/A N/A N/A

Does the media refer more to GUD or ACB?

In the previous week, Aurora Cannabis had 4 more articles in the media than Knight Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.32 beat Aurora Cannabis' score of 0.12 indicating that Knight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Knight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts rate ACB or THCX?

Aurora Cannabis presently has a consensus target price of C$6.67, indicating a potential upside of 9.11%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, equities analysts plainly believe Aurora Cannabis is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ACB or THCX?

Hydropothecary has lower revenue, but higher earnings than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis C$314.07M 1.21 -C$44.16M -C$1.94 N/A Hydropothecary N/A N/A N/A N/A N/A

Does the media refer more to TLRY or ACB?

In the previous week, Aurora Cannabis had 1 more articles in the media than Tilray Brands. MarketBeat recorded 5 mentions for Aurora Cannabis and 4 mentions for Tilray Brands. Aurora Cannabis' average media sentiment score of 0.12 beat Tilray Brands' score of 0.03 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Aurora Cannabis (ACB) Competitors

C$6.06 -0.05 (-0.82%)

As of 10:57 AM Eastern

Compare

ACB vs. CARA, GUD, DHT.UN, THCX, and TLRY

Should you buy Aurora Cannabis stock or one of its competitors? Aurora Cannabis's main competitors and comparable companies include Cara Operations (CARA), Knight Therapeutics (GUD), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aurora Cannabis compare to Cara Operations?

Aurora Cannabis (TSE:ACB) and Cara Operations (TSE:CARA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Cara Operations has lower revenue, but higher earnings than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	1.21	-C$44.16M	-C$1.94	N/A
Cara Operations	N/A	N/A	N/A	N/A	N/A

In the previous week, Aurora Cannabis had 5 more articles in the media than Cara Operations. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for Cara Operations. Aurora Cannabis' average media sentiment score of 0.12 beat Cara Operations' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Cara Operations	Neutral

Aurora Cannabis presently has a consensus price target of C$6.67, suggesting a potential upside of 9.11%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, equities analysts plainly believe Aurora Cannabis is more favorable than Cara Operations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.6% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cara Operations has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. Cara Operations' return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
Cara Operations	N/A	N/A	N/A

Summary

Aurora Cannabis beats Cara Operations on 7 of the 10 factors compared between the two stocks.

How does Aurora Cannabis compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Knight Therapeutics has a beta of -0.449151, indicating that its stock price is 145% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.636856, indicating that its stock price is 36% less volatile than the broader market.

Knight Therapeutics has a net margin of 2.72% compared to Aurora Cannabis' net margin of -9.53%. Knight Therapeutics' return on equity of 1.91% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Aurora Cannabis	-9.53%	-5.21%	-1.87%

22.8% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Knight Therapeutics currently has a consensus price target of C$9.50, suggesting a potential downside of 11.05%. Aurora Cannabis has a consensus price target of C$6.67, suggesting a potential upside of 9.11%. Given Aurora Cannabis' higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Knight Therapeutics has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.92	-C$30.73M	C$0.15	71.20
Aurora Cannabis	C$314.07M	1.21	-C$44.16M	-C$1.94	N/A

In the previous week, Aurora Cannabis had 4 more articles in the media than Knight Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.32 beat Aurora Cannabis' score of 0.12 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Knight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Knight Therapeutics beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to DRI Healthcare Trust?

Aurora Cannabis (TSE:ACB) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Aurora Cannabis presently has a consensus price target of C$6.67, suggesting a potential upside of 9.11%. DRI Healthcare Trust has a consensus price target of C$25.60, suggesting a potential upside of 40.89%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts plainly believe DRI Healthcare Trust is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

DRI Healthcare Trust has a net margin of 5.02% compared to Aurora Cannabis' net margin of -9.53%. DRI Healthcare Trust's return on equity of 2.06% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
DRI Healthcare Trust	5.02%	2.06%	4.22%

DRI Healthcare Trust has lower revenue, but higher earnings than Aurora Cannabis. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	1.21	-C$44.16M	-C$1.94	N/A
DRI Healthcare Trust	C$172.34M	5.79	C$9.73M	-C$0.80	N/A

In the previous week, Aurora Cannabis had 5 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for DRI Healthcare Trust. Aurora Cannabis' average media sentiment score of 0.12 beat DRI Healthcare Trust's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
DRI Healthcare Trust	Neutral

Aurora Cannabis has a beta of 0.636856, suggesting that its share price is 36% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.096953, suggesting that its share price is 90% less volatile than the broader market.

4.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

DRI Healthcare Trust beats Aurora Cannabis on 11 of the 17 factors compared between the two stocks.

How does Aurora Cannabis compare to Hydropothecary?

Aurora Cannabis (TSE:ACB) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Hydropothecary has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. Hydropothecary's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
Hydropothecary	N/A	N/A	N/A

Hydropothecary has lower revenue, but higher earnings than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	1.21	-C$44.16M	-C$1.94	N/A
Hydropothecary	N/A	N/A	N/A	N/A	N/A

In the previous week, Aurora Cannabis had 5 more articles in the media than Hydropothecary. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for Hydropothecary. Aurora Cannabis' average media sentiment score of 0.12 beat Hydropothecary's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Hydropothecary	Neutral

Aurora Cannabis presently has a consensus target price of C$6.67, indicating a potential upside of 9.11%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, equities analysts plainly believe Aurora Cannabis is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.6% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Aurora Cannabis beats Hydropothecary on 7 of the 10 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Tilray Brands currently has a consensus target price of C$13.30, suggesting a potential upside of 186.64%. Aurora Cannabis has a consensus target price of C$6.67, suggesting a potential upside of 9.11%. Given Tilray Brands' higher possible upside, equities research analysts plainly believe Tilray Brands is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Aurora Cannabis had 1 more articles in the media than Tilray Brands. MarketBeat recorded 5 mentions for Aurora Cannabis and 4 mentions for Tilray Brands. Aurora Cannabis' average media sentiment score of 0.12 beat Tilray Brands' score of 0.03 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

4.4% of Tilray Brands shares are held by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tilray Brands has a beta of 3.261139, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.636856, suggesting that its stock price is 36% less volatile than the broader market.

Aurora Cannabis has a net margin of -9.53% compared to Tilray Brands' net margin of -18.92%. Aurora Cannabis' return on equity of -5.21% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-18.92%	-11.41%	-1.41%
Aurora Cannabis	-9.53%	-5.21%	-1.87%

Aurora Cannabis has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$963.10M	0.71	-C$183.24M	-C$1.41	N/A
Aurora Cannabis	C$314.07M	1.21	-C$44.16M	-C$1.94	N/A

Summary

Aurora Cannabis beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACB vs. The Competition

Export

Metric	Aurora Cannabis	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$375.46M	C$12.35B	C$7.25B	C$12.64B
Dividend Yield	N/A	2.63%	2.52%	6.34%
P/E Ratio	-3.12	807.81	275.44	37.52
Price / Sales	1.20	748.69	562.05	8.46
Price / Cash	1.25	86.65	77.16	82.29
Price / Book	0.71	9.26	10.64	4.37
Net Income	-C$44.16M	C$2.83B	C$3.49B	C$299.09M
7 Day Performance	-4.87%	-3.62%	-3.21%	-0.16%
1 Month Performance	14.34%	-7.66%	-7.65%	-2.19%
1 Year Performance	-21.20%	-5.44%	2.92%	14.38%

Aurora Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACB Aurora Cannabis	1.1928 of 5 stars	C$6.06 -0.8%	C$6.67 +10.0%	-17.5%	C$375.46M	C$314.07M	N/A	1,028
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
GUD Knight Therapeutics	0.5858 of 5 stars	C$10.54 +1.7%	C$9.50 -9.9%	+85.1%	C$1.04B	C$547.31M	70.27	830
DHT.UN DRI Healthcare Trust	1.7062 of 5 stars	C$18.22 -0.2%	C$25.60 +40.5%	+26.4%	C$1.00B	C$172.34M	N/A	N/A
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:ACB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurora Cannabis (ACB) Competitors

ACB vs. CARA, GUD, DHT.UN, THCX, and TLRY

How does Aurora Cannabis compare to Cara Operations?

Summary

How does Aurora Cannabis compare to Knight Therapeutics?

Summary

How does Aurora Cannabis compare to DRI Healthcare Trust?

Summary

How does Aurora Cannabis compare to Hydropothecary?

Summary

How does Aurora Cannabis compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACB vs. The Competition

Aurora Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurora Cannabis (ACB) Competitors

ACB vs. CARA, GUD, DHT.UN, THCX, and TLRY

How does Aurora Cannabis compare to Cara Operations?

Which has stronger valuation and earnings, ACB or CARA?

Does the media favor ACB or CARA?

Do analysts rate ACB or CARA?

Do institutionals and insiders have more ownership in ACB or CARA?

Is ACB or CARA more profitable?

Summary

How does Aurora Cannabis compare to Knight Therapeutics?

Which has more volatility & risk, GUD or ACB?

Is GUD or ACB more profitable?

Do institutionals & insiders hold more shares of GUD or ACB?

Do analysts recommend GUD or ACB?

Which has preferable earnings & valuation, GUD or ACB?

Does the media refer more to GUD or ACB?

Summary

How does Aurora Cannabis compare to DRI Healthcare Trust?

Do analysts rate ACB or DHT.UN?

Is ACB or DHT.UN more profitable?

Which has stronger valuation and earnings, ACB or DHT.UN?

Does the media refer more to ACB or DHT.UN?

Which has more volatility & risk, ACB or DHT.UN?

Do institutionals and insiders have more ownership in ACB or DHT.UN?

Summary

How does Aurora Cannabis compare to Hydropothecary?

Is ACB or THCX more profitable?

Which has better valuation and earnings, ACB or THCX?

Does the media prefer ACB or THCX?

Do analysts rate ACB or THCX?

Do insiders & institutionals believe in ACB or THCX?

Summary

How does Aurora Cannabis compare to Tilray Brands?

Do analysts recommend TLRY or ACB?

Does the media refer more to TLRY or ACB?

Do insiders and institutionals hold more shares of TLRY or ACB?

Which has more volatility & risk, TLRY or ACB?

Is TLRY or ACB more profitable?

Which has preferable earnings and valuation, TLRY or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACB vs. The Competition

Aurora Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools